Dynorphin A (1-13) neurotoxicity in vitro: Opioid and non-opioid mechanisms in mouse spinal cord neurons

Experimental Neurology

Volumn 160, Issue 2, 1999, Pages 361-375

  Hauser, Kurt F ^a   Foldes, Jane K ^a   Turbek, Carol S ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

2 amino 5 phosphopentanoic acid; 7 chlorokynurenic acid; Intracellular calcium; MK 801 (Dizocilpine); Neuroprotection; Neurotoxicology; Nor binaltorphimine; opioid receptors, N methyl D aspartate receptors

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 7 CHLOROKYNURENIC ACID; DIZOCILPINE; DYNORPHIN[1-13]; EXCITOTOXIN; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; NORBINALTORPHIMINE; OPIATE ANTAGONIST; OPIATE PEPTIDE;

ANIMAL CELL; ANTINOCICEPTION; ARTICLE; CALCIUM CELL LEVEL; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; SPINAL CORD NERVE CELL; STEREOISOMERISM;

EID: 0032786125     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7235     Document Type: Article

References (95)

1. Arvidsson U., Riedl M., Chakrabarti S., Vulchanova L., Lee J.-H., Nakano A. H., Lin X., Loh H. H., Law P.-Y., Wessendorf M. W., Elde R. The kappa-opioid receptor is primarily postsynaptic: Combined immunohistochemical localization of the receptor and endogenous opioids. Proc. Natl. Acad. Sci. USA. 92:1995;5062-5066.
2. Bakalkin G., Yakovleva T., Reznikov K., Gileva I., Tan No K., Terenius L. Receptor-mediated and nuclear effects of opioids on the cell cycle and apoptosis. Int. Narcot. Res. Conf. Abstr. 29:1998;35.
3. Bakalkin G., Yakovleva T., Terenius L. Prodynorphin gene expression relates to NF-kappaB factors. Mol. Brain Res. 24:1994;301-312.
4. Bakshi R., Newman A. H., Faden A. I. Dynorphin A-(1-17) induces alterations in free fatty acids, excitatory amino acids, and motor function through an opiate- receptor-mediated mechanism. J. Neurosci. 10:1990;3793-3800.
5. Bakshi R., Ni R.-X., Faden A. I. N-Methyl-d-aspartate (NMDA) and opioid receptors mediate dynorphin-induced spinal cord injury: Behavioral and histological studies. Brain Res. 580:1992;255-264.
6. Brewer G. J., Torricelli J. R., Evege E. K., Price P. J. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J. Neurosci. Res. 35:1993;567-576.
7. Caudle R. M., Dubner R. Ifenprodil blocks the excitatory effects of the opioid peptide dynorphin 1-17 on NMDA receptor-mediated currents in the CA3 region of the guinea pig hippocampus. Neuropeptides. 32:1998;87-95.
8. Chavkin C., James I. F., Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science. 215:1982;413-415.
9. Chen L., Gu Y., Huang L.-Y. M. The mechanism of action for the block of NMDA receptor channels by the opioid peptide dynorphin. J. Neurosci. 15:1995;4602-4611.
10. Chen L., Gu Y., Huang L.-Y. M. The opioid peptide dynorphin directly blocks NMDA receptor channels in the rat. J. Physiol. (London). 482:1995;575-581.
11. 2+ block of NMDA-receptor channels as a mechanism of modulation. Nature. 356:1992;521-523.
12. Choi D. W. Excitotoxic cell death. J. Neurobiol. 23:1992;1261-1276.
13. Choi D. W., Hartley D. M. Calcium and glutamate-induced cortical neuronal death. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 71:1993;23-34.
14. Civelli O., Douglass J., Goldstein A., Herbert E. Sequence and expression of the rat prodynorphin gene. Proc. Natl. Acad. Sci. USA. 82:1985;4291-4295.
15. Cox B. M., Molineaux C. J., Jacobs T. P., Rosenberger J. G., Faden A. I. Effects of traumatic injury on dynorphin immunoreactivity in spinal cord. Neuropeptides. 5:1985;571-574.
16. Crain S. M., Shen K. F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol. Sci. 11:1990;77-81.
17. Dawson G., Dawson S. A., Goswami R. Chronic exposure to kappa-opioids enhances the susceptibility of immortalized neurons (F-11kappa 7) to apoptosis-inducing drugs by a mechanism that may involve ceramide. J. Neurochem. 68:1997;2363-2370.
18. Dubner R., Ruda M. A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 15:1992;96-103.
19. Evans C. J., Hammond D. L., Frederickson R. C. A. The opioid peptides. Pasternak G. W. The Opiate Receptors. 1988;23-71 Humana, Clifton.
20. Faden A. I. Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism. J. Neurosci. 12:1992;425-429.
21. Faden A. I. Experimental neurobiology of central nervous system trauma. Crit. Rev. Neurobiol. 7:1993;175-186.
22. Faden A. I., Molineaux C. J., Rosenberger J. G., Jacobs T. P., Cox B. M. Endogenous opioid immunoreactivity in rat spinal cord following traumatic injury. Ann. Neurol. 17:1985;386-390.
23. Faden A. I., Salzman S. Pharmacological strategies in CNS trauma. Trends Pharmacol. Sci. 13:1992;29-35.
24. Gannon R. L., Terrian D. M. U-50, 488H inhibits dynorphin and glutamate release from guinea pig hippocampal mossy fiber terminals. Brain Res. 548:1991;242-247.
25. Gannon R. L., Terrian D. M. Kappa opioid agonists inhibit transmitter release from guinea pig hippocampal mossy fiber synaptosomes. Neurochem. Res. 17:1992;741-747.
26. Genovese R. F., Moreton J. E., Tortella F. C. Evaluation of neuroprotection and behavioral recovery by the kappa-opioid, PD117302, following transient forebrain ischemia. Brain Res. Bull. 34:1994;111-116.
27. Gentile N. T., McIntosh T. K. Antagonists of excitatory amino acids and endogenous opioid peptides in the treatment of experimental central nervous system injury. Ann. Emerg. Med. 22:1993;1028-1034.
28. Goldstein A. Binding selectivity profiles for ligands of multiple receptor types: Focus on opioid receptors. Trends Pharmacol. Sci. 8:1987;456-459.
29. Goldstein A., Tachibana S., Lowney L. I., Hunkapiller M., Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc. Natl. Acad. Sci. USA. 76:1979;6666-6670.
30. Goswami R., Dawson S. A., Dawson G. Cyclic AMP protects against staurosporine and wortmannin-induced apoptosis and opioid-enhanced apoptosis in both embryonic and immortalized (F-11kappa7) neurons. J. Neurochem. 70:1998;1376-1382.
31. 2+ oscillations in cultured hippocampal neurons. Int. Narcot. Res. Conf. Abstr. 29:1998;30.
32. Grynkiewicz G., Poenie M., Tsien R. Y. A new generation of calcium indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
33. Hauser K. F., Gurwell J. A., Turbek C. S. Morphine inhibits Purkinje cell survival and dendritic differentiation in organotypic cultures of the mouse cerebellum. Exp. Neurol. 130:1994;95-105.
34. Hauser K. F., Mangoura D. Diversity of the endogenous opioid system in development: Novel signal transduction translates multiple extracellular signals into neural cell growth and differentiation. Perspect. Dev. Neurobiol. 5:1998;437-449.
35. Hauser K. F., Toran-Allerand C. D. Androgen increases the number of cells in fetal mouse spinal cord cultures: Implications for motoneuron survival. Brain Res. 485:1989;157-164.
36. Herman B. H., Goldstein A. Antinociception and paralysis induced by intrathecal dynorphin A. J. Pharmacol. Exp. Ther. 232:1985;27-32.
37. Huang L.-Y. M. Cellular mechanisms of excitatory and inhibitory actions of opioids. Tseng L. F. The Pharmacology of Opioid Peptides. 1995;131-149 Harwood Academic, Reading.
38. Hudson C. J., Von Voigtlander P. F., Althaus J. S., Scherch H. M., Means E. D. The kappa opioid-related anticonvulsants U-50488H and U-54494A attenuate N-methyl-d-aspartate induced brain injury in the neonatal rat. Brain Res. 564:1991;261-267.
39. Hutchison W. D., Morton C. R., Terenius L. Dynorphin A: In vivo release in the spinal cord of the cat. Brain Res. 532:1990;299-306.
40. Isaac L., O'Malley T. V. Z., Ristic H., Stewart P. MK-801 blocks dynorphin A (1-13)-induced loss of the tail-flick reflex in the rat. Brain Res. 531:1990;83-87.
41. Jarvis C. R., Xiong Z. G., Plant J. R., Churchill D., Lu W. Y., MacVicar B. A., MacDonald J. F. Neurotrophin modulation of NMDA receptors in cultured murine and isolated rat neurons. J. Neurophysiol. 78:1997;2363-2371.
42. Johnson J. W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurones. Nature. 325:1987;529-531.
43. Kolaj M., Cerne R., Randic M. The opioid peptide dynorphin modulates AMPA and kainate responses in acutely isolated neurons from the dorsal horn. Brain Res. 671:1995;227-244.
44. Lai S. L., Gu Y., Huang L. Y. Dynorphin uses a non-opioid mechanism to potentiate N-methyl-d-aspartate currents in single rat periaqueductal gray neurons. Neurosci. Lett. 247:1998;115-118.
45. Laughlin T. M., Vanderah T. W., Lashbrook J., Nichols M. L., Ossipov M., Porreca F., Wilcox G. L. Spinally administered dynorphin A produces long-lasting allodynia: Involvement of NMDA but not opioid receptors. Pain. 72:1997;253-260.
46. Long J. B., Kinney R. C., Malcolm D. S., Graeber G. M., Holaday J. W. Intrathecal dynorphin A (1-13) and (3-13) reduce spinal cord blood flow by non-opioid mechanisms. NIDA Res. Monogr. 75:1986;524-526.
47. Long J. B., Kinney R. C., Malcolm D. S., Graeber G. M., Holaday J. W. Intrathecal dynorphin A1-13 and dynorphin A3-13 reduce rat spinal cord blood flow by non-opioid mechanisms. Brain Res. 436:1987;374-379.
48. Long J. B., Martinez-Arizala A., Echevarria E. E., Tidwell R. E., Holaday J. W. Hindlimb paralytic effects of prodynorphin-derived peptides following spinal subarachnoid injection in rats. Eur. J. Pharmacol. 153:1988;45-54.
49. Long J. B., Martinez-Arizala A., Petras J. M., Holaday J. W. Endogenous opioids in spinal cord injury: A critical evaluation. Central Nerv. Syst. Trauma. 3:1986;295-315.
50. Long J. B., Rigamonti D. D., Oleshansky M. A., Wingfield C. P., Martinez-Arizala A. Dynorphin A-induced rat spinal cord injury: Evidence for excitatory amino acid involvement in a pharmacological model of ischemic spinal cord injury. J. Pharmacol. Exp. Ther. 269:1994;358-366.
51. Macdonald R. L., Werz M. A. Dynorphin A decreases voltage-dependent calcium conductance of mouse dorsal root ganglion neurones. J. Physiol. (London). 377:1986;237-249.
52. Mattson M. P., Barger S. W., Begley J. G., Mark R. J. Calcium, free radicals, and excitotoxic neuronal death in primary cell culture. Methods Cell Biol. 46:1995;187-216.
53. Mattson M. P., Rydel R. E., Lieberburg I., Smith-Swintosky V. L. Altered calcium signaling and neuronal injury: Stroke and Alzheimer's disease as examples. Ann. N.Y. Acad. Sci. 679:1993;1-21.
54. Mattson M. P., Scheff S. W. Endogenous neuroprotection factors and traumatic brain injury: Mechanisms of action and implications for therapy. J. Neurotrauma. 11:1994;3-33.
55. McIntosh T. K., Fernyak S., Hayes R. L., Faden A. I. Beneficial effect of the nonselective opiate antagonist naloxone hydrochloride and the thyrotropin-releasing hormone (TRH) analog YM-14673 on long-term neurobehavioral outcome following experimental brain injury in the rat. J. Neurotrauma. 10:1993;373-384.
56. McIntosh T. K., Fernyak S., Yamakami I., Faden A. I. Central and systemic kappa-opioid agonists exacerbate neurobehavioral response to brain injury in rats. Am. J. Physiol. 267:1994;R665-R672.
57. McIntosh T. K., Hayes R. L., DeWitt D. S., Agura V., Faden A. I. Endogenous opioids may mediate secondary damage after experimental brain injury. Am. J. Physiol. 253:1987;E565-E574.
58. McIntosh T. K., Head V. A., Faden A. I. Alterations in regional concentrations of endogenous opioids following traumatic brain injury in the cat. Brain Res. 425:1987;225-233.
59. Meriney S. D., Ford M. J., Oliva D., Pilar G. Endogenous opioids modulate neuronal survival in the developing avian ciliary ganglion. J. Neurosci. 11:1991;3705-3717.
60. Meriney S. D., Gray D. B., Pilar G. Morphine-induced delay of normal cell death in the avian ciliary ganglion. Science. 228:1985;1451-1453.
61. Moore S. D., Madamba S. G., Schweitzer P., Siggins G. R. Voltage-dependent effects of opioid peptides on hippocampal CA3 pyramidal neurons in vitro. J. Neurosci. 14:1994;809-820.
62. Oleshansky M. A., Long J. B. Ischemic rat spinal cord injury induced by dynorphin A involves elevations in extracellular excitatory amino acids. Soc. Neurosci. Abstr. 17:1991;1268.
63. Olson K. G., Welch S. P. The effects of dynorphin A (1-13) and U50, 488H on free intracellular calcium in guinea pig cerebellar synaptosomes. Life Sci. 48:1991;575-581.
64. Opanashuk L. A., Hauser K. F. Opposing actions of the EGF family and opioids: Heparin binding-epidermal growth factor (HB-EGF) protects mouse cerebellar neuroblasts against the antiproliferative effect of morphine. Brain Res. 804:1998;87-94.
65. Oppenheim R. W. Neurotrophic survival molecules for motoneurons: An embarrassment of riches. Neuron. 17:1996;195-197.
66. Oppenheim R. W., Prevette D., Yin Q. W., Collins F., MacDonald J. Control of embryonic motoneuron survival in vivo by ciliary neurotrophic factor. Science. 251:1991;1616-1618.
67. Orrenius S., Nicotera P. The calcium ion and cell death. J. Neural Transm. Suppl. 43:1994;1-11.
68. Petralia R. S., Yokotani N., Wenthold R. J. Light and electron microscope distribution of the NMDA receptor subunit NMDAR1 in the rat nervous system using a selective anti-peptide antibody. J. Neurosci. 14:1994;667-696.
69. Pohl M., Ballet S., Collin E., Mauborgne A., Bourgoin S., Benoliel J. J., Hamon M., Cesselin F. Enkephalinergic and dynorphinergic neurons in the spinal cord and dorsal root ganglia of the polyarthritic rat - In vivo release and cDNA hybridization studies. Brain Res. 749:1997;18-28.
70. Polakiewicz R. D., Schieferl S. M., Gingras A. C., Sonenberg N., Comb M. J. mu-Opioid receptor activates signaling pathways implicated in cell survival and translational control. J. Biol. Chem. 273:1998;23534-23541.
71. Porreca F., Ossipov M. H., Hruby V. J., Malan T. P. Jr., Lai J. Physiological and pathological actions of dynorphin in pain. Int. Narcot. Res. Conf. Abstr. 29:1998;31.
72. Porter J. D., Hauser K. F. Survival of extraocular muscle in long-term organotypic culture: Differential influence of appropriate and inappropriate motoneurons. Dev. Biol. 160:1993;39-50.
73. Przewlocka B., Machelska H., Lason W. Kappa opioid receptor agonists inhibit the pilocarpine-induced seizures and toxicity in the mouse. Eur. Neuropsychopharmacol. 4:1994;527-533.
74. Riley R. C., Zhao Z. Q., Duggan A. W. Spinal release of immunoreactive dynorphin A (1-8) with the development of peripheral inflammation in the rat. Brain Res. 710:1996;131-142.
75. Rock D. M., Macdonald R. I. The polyamine spermine has multiple actions on N-methyl-d-aspartate receptor single channel currents in cultured cortical neurons. Mol. Pharmacol. 41:1991;83-88.
76. Rothman S. M., Olney J. W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 19:1986;105-111.
77. Sheng W. S., Hu S., Gekker G., Zhu S., Peterson P. K., Chao C. C. Immunomodulatory role of opioids in the central nervous system. Arch. Immunol. Ther. Exp. (Warsz.). 45:1997;359-366.
78. Shukla V. K., Lemaire S. Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides. J. Psychiatry Neurosci. 17:1992;106-119.
79. Shukla V. K., Lemaire S. Non-opioid effects of dynorphins: Possible role of the NMDA receptor. Trends Pharmacol. Sci. 15:1994;420-424.
80. Skilling S. R., Sun X., Kurtz H. J., Larson A. A. Selective potentiation of NMDA-induced activity and release of excitatory amino acids by dynorphin: Possible roles in paralysis and neurotoxicity. Brain Res. 575:1992;272-278.
81. Smith R. G., Appel S. H. Extracts of skeletal muscle increase neurite outgrowth and cholinergic activity of fetal rat spinal motor neurons. Science. 219:1983;1079-1081.
82. Surprenant A., Shen K.-Z., North R. A. Inhibition of calcium currents by noradrenaline, somatostatin and opioids in guinea-pig submucosal neurons. J. Physiol. 431:1990;585-608.
83. Tortella F. C., DeCoster M. A. Kappa opioids: Therapeutic considerations in epilepsy and CNS injury. Clin. Neuropharmacol. 17:1994;403-416.
84. Tucker R. P., Binder L. I., Viereck C., Hemmings B. A., Matus A. I. The sequential appearance of low- and high-molecular-weight forms of MAP2 in the developing cerebellum. J. Neurosci. 8:1988;4503-4512.
85. Vanderah T. W., Laughlin T., Lashbrook J. M., Nichols M. L., Wilcox G. L., Ossipov M. H., Malan T. P. J., Porreca F. Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: Blockade by MK-801 but not naloxone. Pain. 68:1996;275-281.
86. 2+, bioenergetic state, and neurologic outcome following traumatic brain injury in rats. J. Neurosci. 10:1990;3524-3530.
87. Walker J. M., Moises H. C., Coy D. H., Baldrighi G., Akil H. Nonopiate effects of dynorphin and des-Tyr-dynorphin. Science. 218:1982;1136-1138.
88. Walker J. M., Moises H. C., Coy D. H., Young E. A., Watson S. J., Akil H. Dynorphin (1-17): Lack of analgesia but evidence for non-opiate electrophysiological and motor effects. Life Sci. 31:1982;1821-1824.
89. Walker J. M., Tucker D. E., Coy D. H., Walker B. B., Akil H. Des-tyrosine-dynorphin antagonizes morphine analgesia. Eur. J. Pharmacol. 85:1982;121-122.
90. Wang L., Gintzler A. R. Bimodal opioid regulation of cyclic AMP formation: Implications for positive and negative coupling of opiate receptors to adenylyl cyclase. J. Neurochem. 63:1994;1726-1730.
91. Wilkinson K. D., Lee K., Deshpande S., Duerksen-Hughes P., Boss J. M., Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science. 246:1989;670-673.
92. 45Ca into rat cortical synaptosomes by inhibiting N- but not L-type calcium channels. Neuropharmacology. 29:1990;439-444.
93. Ye Z.-C., Sontheimer H. Astrocytes protect neurons from neurotoxic injury by serum glutamate. Glia. 22:1998;237-248.
94. Young E. A., Walker J. M., Houghten R., Akil H. The degradation of dynorphin A in brain tissue in vivo and in vitro. Peptides. 8:1987;701-707.
95. Zhang L., Peoples R. W., Oz M., Harvey-White J., Weight F. F., Brauneis U. Potentiation of NMDA receptor-mediated responses by dynorphin at low extracellular glycine concentrations. J. Neurophysiol. 78:1997;582-590.